TScan Therapeutics, Inc. (TCRX)

NGM – Real Time Price. Currency in USD

1.15

-0.03 (-2.54%)

At close: May 12, 2026, 4:00 PM EDT

1.15

-0.00 (-0.08%)

Pre-market: May 13, 2026, 8:36 AM EDT

06.05.2026

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.26 per share a year ago.

06.05.2026

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™ ) planned for the second quarter of 2026 Initiation of Phase 1 study of TSC-102-A01 and TSC-102-A03 targeting CD45 in patients with HLA types A*01:01 and A*03:01 planned for the second half of 2026 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended March 31, 2026, and provided a corporate update.

27.04.2026

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29ᵗʰ Annual Meeting being held May 11 – 15 in Boston, MA as well as virtually.

08.04.2026

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time.

04.03.2026

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago.

04.03.2026

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2025, and provided business updates.

26.02.2026

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process

Videos

No Data

There is no data to display

Press releases

06.05.2026

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

27.04.2026

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

08.04.2026

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

04.03.2026

TScan Therapeutics, Inc. (TCRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Videos

No Data

Press releases

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Videos

No Data

Press releases

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Search stocks

TScan Therapeutics, Inc. (TCRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Videos

No Data

Press releases

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Videos

No Data

Press releases

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update